AstraZeneca Not Interested In Acquisitions for Scale, Flat Revenues But Growing Margins
This article was originally published in The Pink Sheet Daily
Executive Summary
Little to say on Brilinta, sales momentum driven by Symbicort, Seroquel and Crestor.